- Report
- November 2020
- 450 Pages
Global
From €4459EUR$4,900USD£3,823GBP
- Report
- September 2020
- 700 Pages
Global
From €4459EUR$4,900USD£3,823GBP
- Report
- August 2019
- 42 Pages
Global
€2726EUR$2,995USD£2,337GBP
- Report
- January 2024
- 174 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- March 2025
- 119 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- August 2024
- 84 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- March 2025
- 79 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- January 2024
- 85 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Newsletter
- April 2025
- 3 Pages
Global
From €119EUR$131USD£102GBP
- Report
- November 2021
- 747 Pages
Global
From €3640EUR$4,000USD£3,121GBP
- Report
- December 2023
- 219 Pages
Global
From €3249EUR$3,570USD£2,785GBP
- Report
- May 2023
- 274 Pages
Global
From €3249EUR$3,570USD£2,785GBP
- Book
- March 2024
- 496 Pages
- Book
- April 2020
- 320 Pages
- Book
- February 2020
- 202 Pages
- Book
- November 2024
- 464 Pages

Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer.
Car T therapies are a relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer.
Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less Read more